newsfilter
← Latest News
Business Wire·

SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 Variants

Findings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy